Primary Samples and Relationship to Initial PGC Studies

Supplementary Information

Primary samples and relationship to initial PGC studies

Of the 39,202 samples included in this study (9,369 SCZ cases, 10,410 BP cases, 19,423 controls) 30,175 were included in the initial PGC studies of BP and SCZ (Supplementary Table 1). The additional samples new to this study came from 3BP studies; 1) A French study of 451 BP cases and 1,631 controls, 2) the Swedish sample from the International Cohort Collection for Bipolar Disorder(ICCBD) for824 BP cases and 2,084 controls and 3) an additional 401BP cases and 171 controls from the Thematically Organized Psychosis Study.As well as BP samples collected as part of FaST STEP 2 which included 1,860BP cases. To create a well powered US sample these 1,860 BP cases were combined with 674 BP cases from the GAIN/BIGS study and compared to 1,605 controls from the MIGen consortium. Overlapping individuals were identified (See Methods) across samples and were distributed randomly to the appropriate study in order to reach an ideal 1 control for every case. Supplementary Table 1 presents the samples used in the original PGC studies compared to this study after removing overlapping individuals.

Supplementary Table 1: Description of samples relation to previous PGC samples. (*indicates BP samples were combined into a single US based case samples and combined with MIGen controls)
Previous PGC Study / This PGC Study
PGC SCZ / Country / Platform / SCZ / Controls / SCZ* / Controls*
Cardiff UK / UK / Affymetrix 500K / 472 / 2934 / 464 / 1527
CATIE / United States / Affymetrix 500K; Perlegen 164K / 402 / 207 / 403 / 168
ISC-Aberdeen / UK / Affymetrix 5.0 / 720 / 698 / 718 / 698
ISC-Cardiff / Bulgaria / Affymetrix 6.0 / 527 / 609 / 527 / 609
ISC-Dublin / Ireland / Affymetrix 6.0 / 270 / 860 / 270 / 474
ISC-Edinburgh / UK / Affymetrix 6.0 / 368 / 284 / 365 / 153
ISC-London / UK / Affymetrix 5.0; Affymetrix 500K / 518 / 491 / 520 / 249
ISC-Portugal / Portugal / Affymetrix 5.0 / 346 / 215 / 346 / 216
ISC-SW1 / Sweden / Affymetrix 500K / 168 / 167 / 168 / 167
ISC-SW2 / Sweden / Affymetrix 6.0 / 390 / 229 / 388 / 229
MGS / United States, Australia / Affymetrix 6.0 / 2679 / 2484 / 2670 / 1834
SGENE-Bonn / Germany / Illumina 550K / 474 / 1304 / 474 / 651
SGENE-Copenhagen / Denmark / Illumina Human 610-Quad / 482 / 457 / 483 / 457
SGENE-Munich / Germany / Illumina 300K / 434 / 351 / 433 / 351
SGENE-TOP3 / Norway / Affymetrix 6.0 / 248 / 351 / 245 / 120
SGENE-UCLA / The Netherlands / Illumina 550K / 704 / 631 / 704 / 630
Zucker Hillside / United States / Affymetrix 500K / 192 / 190 / 191 / 190
Total / 9394 / 12462 / 9369 / 8723
PGC BP / BP / Controls / BP* / Controls*
BOMA-Bipolar Study, University of Bonn and CIMH Mannheim / German / Illumina 550 / 675 / 1297 / 673 / 661
Genetic Association Information Network (GAIN) / Bipolar Genome Study (BiGS) / European-American / Affymetrix 6.0 / 542 / 649 / 674* / 0
GlaxoSmithKline (GSK) / British, Canadian or Scottish / Illumina 550 / 890 / 902 / 737 / 903
Pritzker Neuropsychiatric Disorders Research Consortium / European-American / Illumina 550 / 1130 / 718 / 492 / 294
Systematic Treatment Enhancement Program for Bipolar Disorder (STEP1) / European-American / Affymetrix 500K / 922 / 645 / 917 / 915
Systematic Treatment Enhancement Program for Bipolar Disorder (STEP2) / European-American / Affymetrix 5.0 / 659 / 192 / 654 / 114
Thematically Organized Psychosis (TOP3) Study / Norwegian / Affymetrix 6.0 / 203 / 349 / 118 / 119
Trinity College Dublin / Irish / Affymetrix 6.0 / 150 / 797 / 150 / 406
University College London (UCL) / British / Affymetrix 500K / 457 / 495 / 465 / 249
University of Edinburgh / Scottish / Affymetrix 6.0 / 282 / 275 / 279 / 140
Wellcome Trust Case-Control Consortium (WTCCC) / British / Affymetrix 500K / 1571 / 2931 / 1715 / 1408
PGC Samples Total / 7481 / 9250 / 6874 / 5209
Additional BP Samples
French / France / Illumina 650 / 451 / 1631
FaST STEP2 / Translational Genomics Institute 1 (TGEN) / US / Affymetrix 6.0 / 1860* / 1605
International Cohort Collection for Bipolar Disorder(ICCBD) Sweden / Sweden / Affymetrix 6.0 / 824 / 2084
Thematically Organized Psychoses (TOP7) / Norway / Affymetrix 6.0 / 401 / 171
Additional Samples Total / 3536 / 5491
Total / 10410 / 10700

Case only (BP vs SCZ) samples

Supplementary Table 2. Independent sample groups for BP vs SCZ analysis
Population / BP Samples / SCZ Samples / BP / SCZ
US1 / GAIN, FaST STEP 2 / MGS / 2916 / 2674
US2 / STEP1, STEP2 / CATIE / 1573 / 400
Sweden / ICCBD-Sweden / ISC-SW1, ISC-SW2 / 824 / 557
Norway / TOP / SGENE-TOP3 / 518 / 246
Germany / BOMA / SGENE-Bonn, SGENE-Munich / 673 / 907
Ireland / Dublin / ISC-Dublin / 150 / 270
Scotland / University of Edinburgh / ISC-Aberdeen, ISC-Edinburgh / 280 / 1086
UK1 / University College London (UCL) / ISC-London / 482 / 518
UK2 / WTCCC / Cardiff UK / 1836 / 471
Total / 9,252 / 7,129

In order to perform a well powered case only (BP vs SCZ) analysis we combined smaller samples by ancestral population and array technologyto create 9 samples that had sufficient BP and SCZ samples.

Further details on the six genome-wide significant hits

This table provides details on the six most significant SNPs within genomic regions reaching genome-wide significance (p-value > 5x10-8) in the BP+SCZ vs controls GWAS. Odds ratios (OR) and minor allele frequencies (MAF) are provided for both the combined phenotype test and each disease vs controls separately for comparison. Het P is the heterogeneity p-value from the Cochrane Q test, BP vs SCZ p is the p-value from the direct comparison of frequencies between SCZ and BP. PGC BP and PGC SCZ are the association results from the published PGC1 analyses.

Supplementary Table 3. Most significant SNP in 6 genome-wide significant regions from BP+SCZ analysis
Closest gene / SNP / Position (hg18) / BP+SCZ vs controls P / BPvs controls P / SCZ vs controls P / BP+SCZ OR / BP OR / SCZ OR / BPMAF / SCZ MAF / BP control MAF / SCZ control MAF / Het P / BP vs SCZ P / PGC BP / PGC SCZ
CACNA1C / rs1006737 / chr12:2162951..2290787 / 5.53E-13 / 7.43E-08 / 1.65E-06 / 1.12 / 1.13 / 1.12 / 0.348 / 0.347 / 0.324 / 0.327 / 0.85 / 0.54 / 1.7E-05 / 1.4E-06
MHC / rs17693963 / chr6:27337244..33069339 / 3.28E-11 / 4.28E-04 / 3.27E-09 / 0.84 / 0.88 / 0.80 / 0.094 / 0.087 / 0.101 / 0.109 / 0.06 / 0.06 / 1.9E-03 / 7.0E-11
TRANK1 / rs9834970 / chr3:36817627..36935664 / 1.38E-10 / 3.90E-07 / 7.18E-05 / 0.91 / 0.90 / 0.91 / 0.482 / 0.489 / 0.505 / 0.511 / 0.55 / 0.12 / 6.2E-06 / 4.9E-05
MAD1L1 / rs10275045 / chr7:1834618..2305931 / 2.22E-09 / 2.08E-04 / 1.84E-06 / 0.91 / 0.92 / 0.90 / 0.413 / 0.403 / 0.427 / 0.431 / 0.35 / 0.28 / 3.3E-04 / 7.3E-07
PIK3C2A / rs4356203 / chr11:17023194..17381287 / 6.46E-09 / 7.36E-05 / 2.14E-05 / 1.09 / 1.09 / 1.10 / 0.429 / 0.426 / 0.41 / 0.409 / 0.70 / 1.00 / 2.7E-01 / 2.1E-06
IFI44 / rs4650608 / chr1:78942596..79066403 / 8.30E-09 / 1.22E-05 / 1.77E-04 / 0.91 / 0.91 / 0.91 / 0.308 / 0.316 / 0.327 / 0.332 / 0.76 / 0.06 / 2.0E-05 / 1.4E-04

Supplementary Figure 1a-f. Regional association plots for 6 genome-wide significant regions from BP+SCZ vs controls GWAS (labeled by nearest gene).

Supplementary Figure 2a-b. Single disease Manhattan plots.

Full results (p-value, r2) for leave on out BP vs SCZ polygenic analysis

This table provides p-values (Table 4a) and pseudo R2 (Table 4b) from logistic regression on mania score and BP polygenic score with MDS components as covariates for each site individually and each p-value threshold used to create the risk score. Values in bold are nominally significant (p-value < 0.05).

Supplementary Table 4a. P-values for all thresholds by target sample
P-value cutoff / Dublin / GAIN / Germany / Scotland / Sweden / Norway / UCL / US / WTCCC
0.0001 / 2.13E-01 / 6.15E-05 / 9.04E-02 / 1.11E-01 / 8.04E-04 / 1.16E-01 / 1.30E-02 / 4.45E-02 / 1.81E-03
0.001 / 5.87E-01 / 1.41E-03 / 1.16E-03 / 2.46E-02 / 2.03E-04 / 5.78E-01 / 1.83E-02 / 1.06E-02 / 3.08E-03
0.01 / 1.48E-02 / 1.16E-11 / 2.00E-04 / 2.35E-04 / 4.10E-05 / 4.29E-02 / 4.33E-07 / 2.35E-05 / 5.52E-08
0.05 / 9.52E-03 / 8.71E-16 / 5.38E-05 / 8.82E-05 / 2.57E-05 / 3.38E-01 / 7.28E-05 / 4.63E-05 / 2.28E-10
0.1 / 3.65E-03 / 1.84E-16 / 2.80E-05 / 3.65E-05 / 3.04E-06 / 1.85E-01 / 3.60E-05 / 1.10E-05 / 8.59E-12
0.2 / 7.64E-03 / 1.45E-18 / 4.92E-07 / 8.01E-07 / 3.50E-07 / 1.65E-01 / 2.61E-06 / 1.44E-06 / 9.79E-13
0.3 / 1.72E-02 / 8.12E-18 / 3.02E-07 / 6.43E-06 / 1.27E-06 / 3.92E-01 / 7.82E-07 / 5.79E-07 / 8.80E-12
0.4 / 1.05E-02 / 1.91E-19 / 3.09E-07 / 3.37E-06 / 2.30E-06 / 4.74E-01 / 3.06E-07 / 1.80E-07 / 4.66E-12
0.5 / 1.51E-02 / 2.12E-19 / 1.67E-07 / 3.14E-06 / 2.89E-06 / 3.88E-01 / 7.40E-07 / 2.33E-07 / 1.10E-12
1 / 2.06E-02 / 9.64E-20 / 2.55E-07 / 6.11E-06 / 2.22E-06 / 3.40E-01 / 5.22E-07 / 3.05E-07 / 1.59E-12
Supplementary Table 4b. Pseudo r2 for all thresholds by target sample
P-value cutoff / Dublin / GAIN / Germany / Scotland / Sweden / Norway / UCL / US / WTCCC
0.0001 / 0.005 / 0.004 / 0.002 / 0.003 / 0.011 / 0.005 / 0.008 / 0.003 / 0.007
0.001 / 0.001 / 0.002 / 0.009 / 0.006 / 0.013 / 0.001 / 0.007 / 0.005 / 0.006
0.01 / 0.019 / 0.011 / 0.011 / 0.015 / 0.016 / 0.007 / 0.034 / 0.014 / 0.020
0.05 / 0.022 / 0.015 / 0.014 / 0.017 / 0.017 / 0.002 / 0.021 / 0.013 / 0.028
0.1 / 0.028 / 0.016 / 0.015 / 0.019 / 0.021 / 0.003 / 0.023 / 0.015 / 0.032
0.2 / 0.023 / 0.019 / 0.021 / 0.027 / 0.025 / 0.004 / 0.030 / 0.019 / 0.035
0.3 / 0.019 / 0.018 / 0.022 / 0.022 / 0.023 / 0.001 / 0.033 / 0.020 / 0.032
0.4 / 0.022 / 0.020 / 0.022 / 0.024 / 0.022 / 0.001 / 0.035 / 0.022 / 0.033
0.5 / 0.019 / 0.019 / 0.023 / 0.024 / 0.021 / 0.001 / 0.033 / 0.021 / 0.035
1 / 0.018 / 0.020 / 0.022 / 0.023 / 0.022 / 0.002 / 0.034 / 0.021 / 0.034

Full symptom dimensional results from median split analysis

Quantitative manic dimension results by site

Supplementary Table 5. P-values from logistic regression analysis of BP clinical symptoms in SCZ individuals using median split.
P-value threshold / Mania / Depression / Positive Symptoms / Negative Symptoms
<0.0001 / 0.338 / 0.520 / 0.982 / 0.714
<0.001 / 0.083 / 0.159 / 0.890 / 0.550
<0.01 / 0.415 / 0.873 / 0.473 / 0.780
<0.05 / 0.042 / 0.813 / 0.984 / 0.889
<0.1 / 0.012 / 0.886 / 0.733 / 0.732
<0.2 / 0.004 / 0.948 / 0.911 / 0.864
<0.3 / 0.003 / 0.883 / 0.805 / 0.730
<0.4 / 0.005 / 0.928 / 0.860 / 0.719
<0.5 / 0.004 / 0.966 / 0.931 / 0.649
<1 / 0.005 / 0.898 / 0.946 / 0.711

This table shows the nine sites included in the analysis of the manic dimension in SCZ cases, the instrument used to measure mania in each sample, the total size of the sample, the mean and standard deviation of the manic score, the site specific p-value and effect size and the overall p-value if that site was removed

Supplementary Table 6. Logistic regression of BP polygenic score and quantitative mania score within sample and overall.
Sample / Instrument / # individuals / Mean / SD / P-value / Effect / P-value with site removed
Dublin / OPCRIT / 168 / 0.210 / 0.172 / 0.173 / 1.370 / 5.0E-05
MGS / LDPS / 2230 / 0.270 / 0.163 / 0.047 / 1.986 / 1.3E-04
CATIE / PANSS / 304 / 0.224 / 0.200 / 0.583 / -0.549 / 6.0E-06
Munich / PANSS / 428 / 0.246 / 0.210 / 0.054 / 1.929 / 1.3E-04
UCL / OPCRIT / 446 / 0.269 / 0.149 / 0.985 / 0.018 / 1.2E-05
UCLA / CASH / 442 / 0.251 / 0.191 / 0.002 / 3.122 / 7.1E-04
Bonn / OPCRIT / 466 / 0.258 / 0.177 / 0.003 / 2.939 / 3.2E-04
Denmark / OPCRIT / 92 / 0.263 / 0.159 / 0.277 / -1.094 / 1.0E-05
Aberdeen / OPCRIT / 619 / 0.264 / 0.165 / 0.020 / 2.334 / 2.3E-04
Oslo / PANSS / 202 / 0.256 / 0.196 / 0.928 / -0.090 / 9.8E-06
Cardiff / OPCRIT / 380 / 0.273 / 0.137 / 0.460 / 0.740 / 4.0E-05
All / 5777 / 0.261 / 0.172 / 2.5E-05 / 4.218

Supplementary Table 7. Genome-wide significant hits before and after removing 186 individuals with particularly high BP polygenic score and manic factor score

With 186 samples removed
Closest gene / SNP / Position (hg18) / BP+SCZ P / BP P / SCZ P / Het P / BP+SCZ P / BP P / SCZ P
CACNA1C / rs1006737 / chr12:2162951..2290787 / 5.53E-13 / 7.43E-08 / 1.65E-06 / 0.85 / 8.50E-13 / 7.43E-08 / 2.48E-06
MHC / rs17693963 / chr6:27337244..33069339 / 3.28E-11 / 4.28E-04 / 3.27E-09 / 0.06 / 5.08E-11 / 0.0004275 / 4.84E-09
TRANK1 / rs9834970 / chr3:36817627..36935664 / 1.38E-10 / 3.90E-07 / 7.18E-05 / 0.55 / 1.26E-10 / 3.90E-07 / 6.65E-05
MAD1L1 / rs10275045 / chr7:1834618..2305931 / 2.22E-09 / 2.08E-04 / 1.84E-06 / 0.35 / 3.02E-09 / 0.0002078 / 2.56E-06
PIK3C2A* / rs4356203 / chr11:17023194..17381287 / 6.46E-09 / 7.36E-05 / 2.14E-05 / 0.7 / 4.46E-09 / 7.36E-05 / 1.40E-05
IFI44L / rs4650608 / chr1:78942596..79066403 / 8.30E-09 / 1.22E-05 / 1.77E-04 / 0.76 / 1.03E-08 / 1.22E-05 / 2.21E-04

Supplementary Figure 3. Odds ratios of 22 previously identified genome-wide significant hits both before (red) and after (blue) removing 186 individuals with particularly high BP polygenic score and manic factor score.

Supplementary Figure 4. Average pseudo R2 values for polygenic prediction of BP vs SCZ phenotype into the target sample where all other samples were used for discovery with 186 samples removed

Authors and Affiliations

PGC Workgroup(s) / First name / Last name / Affiliation / Country
BP / Devin / Absher / HudsonAlpha Institute for Biotechnology, Huntsville, Alabama, USA. / USA
SCZ / Ingrid / Agartz / NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine; University of Oslo; Department of Research; Diakonhjemmet Hospital; Oslo; Norway / Norway
BP / Huda / Akil / Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, Michigan, USA. / USA
SCZ / Farooq / Amin / Department of Psychiatry and Behavioral Sciences; Emory University and Atlanta Veterans Affairs Medical Center; Atlanta; Georgia; USA / USA
SCZ, BP / Ole A / Andreassen / NORMENT, KG Jebsen Centre for Psychosis Research; Institute of Clinical Medicine; University of Oslo; Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway / Norway
BP / Adebayo / Anjorin / Molecular Psychiatry Laboratory, Mental Health Sciences Unit, University College London, London, UK. / UK
SCZ / Maria H. / Azevedo / Faculty of Medicine, University of Coimbra, Coimbra, Portugal / Portugal
BP / Lena / Backlund / Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. / Sweden
BP / Judith A / Badner / Department of Psychiatry, University of Chicago, Chicago, Illinois, USA. / USA
BP / Jack D / Barchas / Department of Psychiatry, Weill Medical College, Cornell University, New York, New York, USA. / USA
BP / Thomas B / Barrett / Portland Veterans Affairs Medical Center, Portland, Oregon, USA. / USA
SCZ, BP / Nicholas / Bass / Molecular Psychiatry Laboratory, Rockefeller Building
Mental Health Sciences Unit, Faculty of Brain Sciences
University College London, 21 University Street, London, WC1E 6BT / UK
BP / Michael / Bauer / Department of Psychiatry and Psychotherapy; ENBREC Group; University Hospital Carl Gustav Carus; Dresden; Germany. / Germany
BP / Frank / Bellivier / INSERM, U955, Psychiatrie Génétique, Créteil, France.; Université Paris Est, Faculté de Médecine, Créteil, France.; Assistance Publique–Hôpitaux de Paris (AP -HP); Hôpital H. Mondor–A. Chenevier; Département de Psychiatrie; Créteil; France.; ENBREC group; Fondation Fondamental; Créteil; France. / France
BP / Sarah E / Bergen / Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA. / USA
BP / Wade / Berrettini / Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA. / USA
SCZ / Donald W / Black / Department of Psychiatry; University of Iowa Carver College of Medicine; Iowa City; Iowa; USA / USA
SCZ, BP / Douglas H R / Blackwood / Division of Psychiatry; University of Edinburgh; Royal Edinburgh Hospital; Edinburgh; Scotland; UK / UK
BP / Cinnamon S / Bloss / The Scripps Translational Science Institute and Scripps Health, La Jolla, California, USA. / USA
BP / Michael / Boehnke / Department of Biostatistics and Center for Statistical Genetics, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA. / USA
BP / Gerome / Breen / Social, Genetic and Developmental Psychiatry (SGDP) Centre, The Institute of Psychiatry, King’s College London, De Crespigny Park Denmark Hill, London, UK.; University of Aberdeen, Institute of Medical Sciences, Foresterhill, Aberdeen, UK. / UK
BP / René / Breuer / Department of Genetic Epidemiology in Psychiatry; Central Institute of Mental Health; University of Heidelberg; Mannheim; Germany / Germany
SCZ / Richard / Bruggerman / University Medical Center Groningen, Department of Psychiatry, University of Groningen, Groningen, The Netherlands / The Netherlands
SCZ / Nancy G / Buccola / School of Nursing; Louisiana State University Health Sciences Center; New Orleans; Louisiana; USA / USA
BP / William E / Bunney / Department of Psychiatry and Human Behavior, University of California, Irvine, California, USA. / USA
BP / Margit / Burmeister / Department of Human Genetics, Department of Psychiatry, Molecular and Behavioral Neuroscience Institute, University of Michigan, Ann Arbor, Michigan, USA. / USA
BP, SCZ / William / Byerley / Department of Psychiatry; University of California at San Francisco and NCIRE (Northern California Institute for Research And Education); San Francisco; California; USA / USA
BP / Sian / Caesar / Department of Psychiatry, School of Clinical and Experimental Medicine, Birmingham University, Birmingham, UK. / UK
SCZ / Wiepke / Cahn / Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands / The Netherlands
SCZ / Rita M / Cantor / UCLA Center for Neurobehavioral Genetics; University of California at Los Angeles; Department of Human Genetics; University of California at Los Angeles; Los Angeles; California; USA / USA
BP / Kim / Chambert / Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA. / USA
SCZ / Khalid / Choudhury / Molecular Psychiatry Laboratory, Rockefeller Building
Mental Health Sciences Unit, Faculty of Brain Sciences
University College London, 21 University Street, London, WC1E 6BT / UK
BP, SCZ / Sven / Cichon / Dept. of Genomics; Life & Brain Center; University of Bonn; Bonn; Institute of Neuroscience and Medicine (INM -1); Research Center Juelich; Juelich; Institute of Human Genetics; Unviersity of Bonn; Bonn; Germany / Germany
SCZ / C. Robert / Cloninger / Washington University / USA
BP / David A / Collier / Social; Genetic and Developmental Psychiatry Centre; Institute of Psychiatry; King's College; London; England; UK / UK
BP, SCZ / Aiden / Corvin / Neuropsychiatric Genetics Research Group; Department of Psychiatry and Institute of Molecular Medicine; Trinity College Dublin; Dublin; Ireland / Ireland
BP / William H / Coryell / University of Iowa / USA
BP, SCZ / Nicholas / Craddock / Cardiff University School of Medicine / UK
BP / David W / Craig / The Translational Genomics Research Institute, Phoenix, Arizona, USA. / USA
SCZ / David / Curtis / Molecular Psychiatry Laboratory, Rockefeller Building,
Mental Health Sciences Unit, Faculty of Brain Sciences
University College London, 21 University Street, London, WC1E 6BT / UK
Analysis, BP, SCZ / Mark / Daly / Analytic and Translational Genetics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA. / USA
SCZ / Susmita / Datta / Molecular Psychiatry Laboratory, Rockefeller Building
Mental Health Sciences Unit, Faculty of Brain Sciences
University College London, 21 University Street, London, WC1E 6BT / UK
BP / Richard / Day / Division of Neuroscience, Medical Research Institute, University of Dundee, Ninewells Hospital & Medical School, Dundee, UK. / UK
BP / Franziska A / Degenhardt / (1) Dept. of Genomics; Life & Brain Center; University of Bonn; Bonn; (2) Institute of Human Genetics; Unviersity of Bonn; Bonn; Germany / Germany
SCZ / Lieuwe / De Haan / Academic Medical Centre University of Amsterdam, Department of Psychiatry, Amsterdam, The Netherlands / The Netherlands
BP, SCZ / Srdjan / Djurovic / NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Medical Genetics, Oslo University Hospital, Oslo, Norway. / Norway
SCZ / Jubao / Duan / Department of Psychiatry and Behavioral Sciences; NorthShore University HealthSystem and University of Chicago; Evanston; Illinois; USA / USA
BP, SCZ / Frank / Dudbridge / Department of Non -communicable Disease Epidemiology; London School of Hygiene and Tropical Medicine; London; England; UK / UK
BP / Howard J / Edenberg / Department of Biochemistry and Molecular Biology, Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA / USA
BP / Amanda / Elkin / Social, Genetic and Developmental Psychiatry (SGDP) Centre, The Institute of Psychiatry, King’s College London, De Crespigny Park Denmark Hill, London, UK. / UK
BP / Bruno / Etain / INSERM, U955, Psychiatrie Génétique; Université Paris Est, Faculté de Médecine; Assistance Publique–Hôpitaux de Paris (AP -HP), Hôpital H. Mondor–A. Chenevier; Département de Psychiatrie; ENBREC group; Fondation Fondamental; Créteil; France. / France
SCZ / Ayman / Fanous / Washington VA Medical Center; Department of Psychiatry; Georgetown University School of Medicine; Washington; DC; USA; Department of Psychiatry; Virginia Commonwealth University School of Medicine; Richmond; Virginia; USA / USA
BP / Anne E / Farmer / Social, Genetic and Developmental Psychiatry (SGDP) Centre, The Institute of Psychiatry, King’s College London, De Crespigny Park Denmark Hill, London, UK. / UK
BP / Manuel A / Ferreira / Queensland Institute of Medical Research, Brisbane, Australia. / Australia
BP / I Nicol / Ferrier / Division of Neuroscience, Medical Research Institute, University of Dundee, Ninewells Hospital & Medical School, Dundee, UK. / UK
BP / Matthew / Flickinger / Department of Biostatistics and Center for Statistical Genetics, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA. / USA
BP / Tatiana / Foroud / Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA. / USA
BP / Josef / Frank / Department of Genetic Epidemiology in Psychiatry; Central Institute of Mental Health; University of Heidelberg; Mannheim; Germany / Germany
BP / Christine / Fraser / Medical Research Council (MRC) Centre for Neuropsychiatric Genetics and Genomics, Henry Wellcome Building, School of Medicine, Cardiff University, Heath Park, Cardiff, UK. / UK
SCZ / Robert / Freedman / Department of Psychiatry; University of Colorado Denver; Aurora; Colorado; USA / USA
SCZ / Nelson B / Freimer / UCLA Center for Neurobehavioral Genetics; University of California at Los Angeles; Los Angeles; California; USA / USA
SCZ / Marion / Friedl / Molecular and Clinical Neurobiology; Department of Psychiatry; Ludwig - Maximilians -University; Munich; Germany / Germany
BP / Louise / Frisén / Department of Molecular Medicine, Karolinska Institutet, Stockholm, Sweden. / Sweden
BP / Janice / Fullerton / Prince of Wales Medical Institute; Sydney; Australia.; University of New South Wales; Sydney; Australia. / Australia
SCZ / Pablo V / Gejman / Department of Psychiatry and Behavioral Sciences; NorthShore University HealthSystem and University of Chicago; Evanston; Illinois; USA / USA
SCZ / Lyudmila / Georgieva / MRC Centre for Neuropsychiatric Genetics and Genomics; Department of Psychological Medicine and Neurology; School of Medicine; Cardiff University; Cardiff; Wales; UK / UK
BP / Elliot S / Gershon / Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn, Bonn, Germany. / Germany
SCZ / Ina / Giegling / Molecular and Clinical Neurobiology; Department of Psychiatry; Ludwig - Maximilians -University; Munich; Germany / Germany
BP, SCZ / Michael / Gill / Neuropsychiatric Genetics Research Group, Department of Psychiatry and Institute of Molecular Medicine, Trinity College Dublin, Dublin, Ireland. / Ireland
BP / Katherine / Gordon -Smith / Medical Research Council (MRC) Centre for Neuropsychiatric Genetics and Genomics, Henry Wellcome Building, School of Medicine, Cardiff University, Heath Park, Cardiff, UK.; Department of Psychiatry, School of Clinical and Experimental Medicine, Birmingham University, Birmingham, UK. / UK
BP / Elaine K / Green / Medical Research Council (MRC) Centre for Neuropsychiatric Genetics and Genomics, Henry Wellcome Building, School of Medicine, Cardiff University, Heath Park, Cardiff, UK. / UK
BP / Tiffany A / Greenwood / Department of Psychiatry, University of California San Diego, La Jolla, California, USA / USA
BP / Detelina / Grozeva / Medical Research Council (MRC) Centre for Neuropsychiatric Genetics and Genomics, Henry Wellcome Building, School of Medicine, Cardiff University, Heath Park, Cardiff, UK. / UK
BP / Weihua / Guan / Division of Biostatistics, School of Public Health
University of Minnesota, Minneapolis, MN USA. / USA
BP, SCZ / Hugh / Gurling / Molecular Psychiatry Laboratory, Rockefeller Building
Mental Health Sciences Unit, Faculty of Brain Sciences
University College London, 21 University Street, London, WC1E 6BT / UK
BP / Ómar / Gustafsson / deCODE Genetics, Sturlugata 8 101 Reykjavík, Iceland. / Iceland
BP, SCZ / Marian L / Hamshere / Medical Research Council (MRC) Centre for Neuropsychiatric Genetics and Genomics, Henry Wellcome Building, School of Medicine, Cardiff University, Heath Park, Cardiff, UK.; Biostatistics and Bioinformatics Unit, Cardiff University School of Medicine, Cardiff, UK. / UK
SCZ / Thomas F / Hansen / Institute of Biological Psychiatry, MHC Sct. Hans, Mental Health Services Copenhagen; The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH; Denmark / Denmark